These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 17295045)
1. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045 [TBL] [Abstract][Full Text] [Related]
2. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre. Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095 [TBL] [Abstract][Full Text] [Related]
3. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005 [TBL] [Abstract][Full Text] [Related]
4. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme. Steger GG; Gips M; Simon SD; Lluch A; Vinholes J; Kaufman B; Wardley A; Mauriac L Cancer Treat Rev; 2005; 31 Suppl 2():S10-6. PubMed ID: 16198057 [TBL] [Abstract][Full Text] [Related]
5. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793 [TBL] [Abstract][Full Text] [Related]
6. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment? Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354 [TBL] [Abstract][Full Text] [Related]
7. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer. Abram P; Maass N; Rea D; Simon SD; Steger GG Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128 [TBL] [Abstract][Full Text] [Related]
8. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340 [TBL] [Abstract][Full Text] [Related]
9. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099 [TBL] [Abstract][Full Text] [Related]
10. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre. Cheung KL; Owers R; Robertson JF Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292 [TBL] [Abstract][Full Text] [Related]
11. [Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer]. Martínez Marín V; Muñoz Martín AJ; Viñuela Benéitez MC; García Alfonso P; Alonso Muñoz A; Pérez Manga G Med Clin (Barc); 2009 Sep; 133(10):371-4. PubMed ID: 19339025 [TBL] [Abstract][Full Text] [Related]
12. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Bartsch R; Mlineritsch B; Gnant M; Niernberger T; Pluschnig U; Greil R; Wenzel C; Sevelda P; Thaler J; Rudas M; Pober M; Zielinski CC; Steger GG; Breast Cancer Res Treat; 2009 May; 115(2):373-80. PubMed ID: 18661231 [TBL] [Abstract][Full Text] [Related]
13. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098 [TBL] [Abstract][Full Text] [Related]
14. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA; J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423 [TBL] [Abstract][Full Text] [Related]
15. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Howell A; Robertson JF; Abram P; Lichinitser MR; Elledge R; Bajetta E; Watanabe T; Morris C; Webster A; Dimery I; Osborne CK J Clin Oncol; 2004 May; 22(9):1605-13. PubMed ID: 15117982 [TBL] [Abstract][Full Text] [Related]
16. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Pritchard KI; Rolski J; Papai Z; Mauriac L; Cardoso F; Chang J; Panasci L; Ianuli C; Kahan Z; Fukase K; Lindemann JP; Macpherson MP; Neven P Breast Cancer Res Treat; 2010 Sep; 123(2):453-61. PubMed ID: 20632084 [TBL] [Abstract][Full Text] [Related]
17. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664 [TBL] [Abstract][Full Text] [Related]
18. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Vergote I; Robertson JF Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759 [TBL] [Abstract][Full Text] [Related]
19. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients. Warm M; Kates R; Overkamp F; Thomas A; Harbeck N Breast Cancer Res Treat; 2011 Jan; 125(1):127-36. PubMed ID: 20960229 [TBL] [Abstract][Full Text] [Related]
20. Fulvestrant ('Faslodex'): current and future role in breast cancer management. Howell A Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]